Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?

Group 1: Clinical Trial Results - Relay Therapeutics' zovegalisib demonstrated a median progression-free survival (PFS) of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer [1] - Median PFS was 11.2 months in patients with kinase mutations and 11.0 months in patients with non-kinase mutations [1][2] Group 2: Safety Profile - The safety profile of the 400mg BID fed regimen was consistent with previous findings from the 600mg BID fasted dose, reinforcing the drug's potential as a treatment option [2] Group 3: Stock Performance - Relay Therapeutics shares increased by 195.16% over the past 12 months, currently trading 8.6% above its 20-day simple moving average (SMA) and 30.3% above its 100-day SMA [3] - The RSI is at 60.72, indicating neutral territory, while the MACD is at 0.5310, suggesting bullish momentum [3][4] Group 4: Analyst Consensus - The stock carries a Buy Rating with an average price target of $17.20, with recent analyst actions including Guggenheim raising the target to $22.00 and Wells Fargo raising it to $15.00 [5][6] - Benzinga Edge scorecard indicates strong momentum, with a bullish score of 98.01, showing that the stock is outperforming the broader market [5] Group 5: Price Action and Support/Resistance Levels - Relay Therapeutics shares were down 1.45% at $10.21 at the time of publication, with key resistance at $11.50 and key support at $9.00 [6]